Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Target Price at $10.80

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $10.80.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, February 26th.

Insiders Place Their Bets

In related news, VP Christopher Ray Aker sold 38,547 shares of Regulus Therapeutics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the transaction, the vice president now directly owns 54,634 shares of the company’s stock, valued at $68,838.84. The trade was a 41.37 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Joseph P. Hagan purchased 50,000 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were purchased at an average price of $1.09 per share, with a total value of $54,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 260,808 shares in the company, valued at $284,280.72. The trade was a 23.72 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 223,998 shares of company stock valued at $282,237. 4.35% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regulus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of RGLS. Creative Planning bought a new stake in shares of Regulus Therapeutics in the third quarter worth about $26,000. Jane Street Group LLC bought a new stake in shares of Regulus Therapeutics in the 3rd quarter worth approximately $46,000. PEAK6 LLC bought a new position in shares of Regulus Therapeutics during the fourth quarter valued at approximately $95,000. Velan Capital Investment Management LP bought a new position in Regulus Therapeutics in the 4th quarter worth $111,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 52,059 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock opened at $1.29 on Monday. Regulus Therapeutics has a 1 year low of $0.83 and a 1 year high of $3.79. The firm has a market cap of $84.50 million, a PE ratio of -1.21 and a beta of 1.42. The company has a 50 day simple moving average of $1.30 and a two-hundred day simple moving average of $1.47.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.